Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Sees Large Decrease in Short Interest

Emmaus Life Sciences, Inc. (OTCMKTS:EMMAGet Free Report) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 700 shares, a decrease of 93.6% from the January 31st total of 11,000 shares. Based on an average daily volume of 11,700 shares, the short-interest ratio is currently 0.1 days.

Emmaus Life Sciences Price Performance

Shares of Emmaus Life Sciences stock traded down $0.01 during trading on Wednesday, reaching $0.12. 15,000 shares of the stock traded hands, compared to its average volume of 23,983. The company has a market capitalization of $7.50 million, a price-to-earnings ratio of -1.21 and a beta of 1.64. The business has a fifty day simple moving average of $0.10 and a two-hundred day simple moving average of $0.12. Emmaus Life Sciences has a 52-week low of $0.05 and a 52-week high of $0.40.

About Emmaus Life Sciences

(Get Free Report)

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Read More

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.